1
                                  Exhibit 99.2


                Atrix Completes $50 Million Private Offering of
                   7% Convertible Subordinated Notes due 2004

    FORT COLLINS, Colo., November 24, 1997 -- Atrix Laboratories, Inc. (Nasdaq:
ATRX) announced today that it has completed an agreement to sell $50 million of
its 7% convertible subordinated notes due 2004 (the "Notes") in an offering
within the United States to qualified institutional investors and outside the
United States to non-U.S.  investors.  The offering is expected to close on
November 26, 1997.  The Company has granted the initial purchasers a 30-day
option to purchase an additional $7.5 million of notes to cover
over-allotments, if any.

    The Notes will be convertible into shares of common stock of the Company at
a conversion price of $19 per share for a total of approximately 2.63 million
shares of common stock of the Company (3.03 million shares if the initial
purchasers' over-allotment option is exercised in full).  The notes have a
seven-year term and will be non-callable for the first three years.

    The Company stated that it intends to use the proceeds of the offering for
general corporate purposes, including research and development,
commercialization of its products and to acquire complementary products,
technologies and businesses.

    This announcement is neither an offer to sell nor a solicitation to buy any
of these securities.

    The securities to be offered will not be registered under the Securities
Act of 1933, as amended (the "Act"), or any state securities laws, and unless
so registered, may not be offered or sold in the United States except pursuant
to an exemption from, or in a transaction not subject to, the registration
requirements of the Act and applicable state securities laws.

    Atrix Laboratories, Inc. develops, manufactures and markets dental, medical
and veterinary products based on its proprietary ATRIGEL(R) biodegradable
polymeric technology, which can be used for a broad range of drug delivery and
biomaterial applications.